Alphiya Tsygankova

Dr. Alphiya Tsygankova


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2020 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
DVDanila Vasilchenko
Danila Vasilchenko
PTPolina Topchiyan
Polina Topchiyan
ATAlphiya Tsygankova
Alphiya Tsygankova
TATatyana Asanova
Tatyana Asanova
Boris A. KolesovBoris A. Kolesov
Boris A. Kolesov
Ekaterina A. KozlovaEkaterina A. Kozlova
Ekaterina A. Kozlova

30 September 2020 in Nanoscale
Verified
Journal Article
Closed access
PDF file
YVYuri A. Vorotnikov
Yuri A. Vorotnikov
ENEvgeniya D. Novikova
Evgeniya D. Novikova
ASAnastasiya O. Solovieva
Anastasiya O. Solovieva
DSDaniil V. Shanshin
Daniil V. Shanshin
ATAlphiya Tsygankova
Alphiya Tsygankova
ASAlexander M. Shestopalov
Alexander M. Shestopalov
Monoclonal antibodies (mAb) demonstrate great potential as immunotherapy agents for the treatment of diseases such as cancer as well as tagging for the targeted delivery of multicomponent therapeutic or diagnostic systems. Nevertheless, the large physical size, poor stability of mAbs and abnormal allergic reactions still remain the main issues affecting their generalised use. Single-domain antibodies (sdAb) are seen as the next generation of antibody derived therapeutics and diagnostics. This work presents the optimised production method for HER2-specific sdAb C7b, which led to an ∼11-fold increase in protein yield. In addition, the in vitro and in vivo efficiencies of the targeted delivery of a model nanoparticle cargo (50 nm silica particles doped with Mo6 phosphorescent clusters) conjugated to C7b against those conjugated to HER2-specific trastuzumab is benchmarked. Specifically, this paper demonstrates the significantly higher rate of accumulation in and excretion from xenograft cancer tissue of nanoparticles with C7b, which is of particular importance for diagnostics, i.e. delivery of imaging agents.

1 August 2016 in Talanta
Verified
Journal Article
Closed access
NMNikolay Medvedev
Nikolay Medvedev
ASAnastasiya V. Shaverina
Anastasiya V. Shaverina
ATAlphiya Tsygankova
Alphiya Tsygankova
ASAnatoly I. Saprykin
Anatoly I. Saprykin

1 March 2020 in Russian Chemical Bulletin
Verified
Journal Article
Closed access
PDF file
ATAlphiya Tsygankova
Alphiya Tsygankova
VKVladimir Kanygin
Vladimir Kanygin
AKA. I. Kasatova
A. I. Kasatova
EZE. L. Zav’yalov
E. L. Zav’yalov
TGT. Ya. Gusel’nikova
T. Ya. Gusel’nikova
RMR. A. Mukhamadiyarov
R. A. Mukhamadiyarov

14 January 2022 in Biology
Verified
Journal Article
Open access
PDF file
VKVladimir Kanygin
Vladimir Kanygin
Aleksandr KichiginAleksandr Kichigin
Aleksandr Kichigin
Alexander ZaboronokAlexander Zaboronok
Alexander Zaboronok
Anna KasatovaAnna Kasatova
Anna Kasatova
EPElena Petrova
Elena Petrova
Sergey TaskaevSergey Taskaev
Sergey Taskaev
(1) Background: accelerator-based neutron sources are a new frontier for BNCT but many technical issues remain. We aimed to study such issues and results in larger-animal BNCT (cats and dogs) with naturally occurring, malignant tumors in different locations as an intermediate step in translating current research into clinical practice. (2) Methods: 10 pet cats and dogs with incurable, malignant tumors that had no treatment alternatives were included in this study. A tandem accelerator with vacuum insulation was used as a neutron source. As a boron-containing agent, 10B-enriched sodium borocaptate (BSH) was used at a dose of 100 mg/kg. Animal condition as well as tumor progression/regression were monitored. (3) Results: regression of tumors in response to treatment, improvements in the overall clinical picture, and an increase in the estimated duration and quality of life were observed. Treatment-related toxicity was mild and reversible. (4) Conclusions: our study contributes to preparations for human BNCT clinical trials and suggests utility for veterinary oncology.

8 December 2021 in Membranes
Verified
Journal Article
Open access
PDF file
Anton ManakhovAnton Manakhov
Anton Manakhov
NSNatali Sitnikova
Natali Sitnikova
ATAlphiya Tsygankova
Alphiya Tsygankova
AAAlexander Yurievich Alekseev
Alexander Yurievich Alekseev
LALyubov S. Adamenko
Lyubov S. Adamenko
Anastasiya SolovievaAnastasiya Solovieva
Anastasiya Solovieva
Copper-coated nanofibrous materials are desirable for catalysis, electrochemistry, sensing, and biomedical use. The preparation of copper or copper-coated nanofibers can be pretty challenging, requiring many chemical steps that we eliminated in our robust approach, where for the first time, Cu was deposited by magnetron sputtering onto temperature-sensitive polymer nanofibers. For the first time, the large-scale modeling of PCL films irradiation by molecular dynamics simulation was performed and allowed to predict the ions penetration depth and tune the deposition conditions. The Cu-coated polycaprolactone (PCL) nanofibers were thoroughly characterized and tested as antibacterial agents for various Gram-positive and Gram-negative bacteria. Fast release of Cu2+ ions (concentration up to 3.4 µg/mL) led to significant suppression of E. coli and S. aureus colonies but was insufficient against S. typhimurium and Ps. aeruginosa. The effect of Cu layer oxidation upon contact with liquid media was investigated by X-ray photoelectron spectroscopy revealing that, after two hours, 55% of Cu atoms are in form of CuO or Cu(OH)2. The Cu-coated nanofibers will be great candidates for wound dressings thanks to an interesting synergistic effect: on the one hand, the rapid release of copper ions kills bacteria, while on the other hand, it stimulates the regeneration with the activation of immune cells. Indeed, copper ions are necessary for the bacteriostatic action of cells of the immune system. The reactive CO2/C2H4 plasma polymers deposited onto PCL-Cu nanofibers can be applied to grafting of viable proteins, peptides, or drugs, and it further explores the versatility of developed nanofibers for biomedical applications use.